熊去氧胆酸治疗原发性胆汁性胆管炎预防肝移植或死亡的需治疗人数
基于全球PBC研究组数据库3902例患者,中位随访7.8年,采用逆概率治疗加权校正Cox分析计算UDCA预防肝移植或死亡的NNT。总体HR为0.46,5年无肝移植生存率(未治疗)81%,5年NNT为11;肝硬化患者NNT5y为4,非肝硬化为20;ALP≤2×ULN、2-4×ULN、>4×ULN者NNT5y分别为26、11、5。
要点
- UDCA可显著降低PBC患者肝移植或死亡风险,总体5年NNT为11。
- 肝硬化患者5年NNT为4,获益远高于非肝硬化患者的20。
- 基线ALP越高,5年NNT越小(>4×ULN者NNT为5)。
核心结论
- UDCA预防肝移植或死亡的绝对临床疗效随基线预后特征变化,但整体均较高。
- 应尽早启动UDCA治疗所有PBC患者,并可能提高患者依从性。
研究设计与样本
- 基于全球PBC研究组数据库的回顾性队列研究,纳入3902例患者,中位随访7.8年(4.1-12.1年)。
- 采用逆概率治疗加权校正的Cox比例风险分析计算UDCA的HR,并据此计算NNT。
主要发现
- UDCA总体HR为0.46(95%CI 0.40-0.52),未治疗5年无肝移植生存率为81%(95%CI 79-82)。
- 预防5年内一例肝移植或死亡的NNT(NNT5y)为11(95%CI 9-13)。
- 肝硬化与非肝硬化患者UDCA的HR相似(0.33 vs 0.31),但NNT5y分别为4(95%CI 3-5)和20(95%CI 14-34)。
- ALP≤2×ULN、2-4×ULN、>4×ULN患者的NNT5y分别为26(95%CI 15-70)、11(95%CI 8-17)、5(95%CI 4-8)。
临床怎么用
- 临床中应尽早对所有PBC患者启动UDCA治疗,尤其肝硬化或高ALP患者绝对获益更大。
- 可用NNT5y向患者解释绝对获益,以提高治疗依从性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: The clinical benefit of ursodeoxycholic acid (UDCA) in primary biliary cholangitis (PBC) has never been reported in absolute measures. The aim of this study was to assess the number needed to treat (NNT) with UDCA to prevent liver transplantation (LT) or death among patients with PBC. METHODS: The NNT was calculated based on the untreated LT-free survival and HR of UDCA with respect to LT or death as derived from inverse probability of treatment weighting-adjusted Cox proportional hazard analyses within the Global PBC Study Group database. RESULTS: We included 3902 patients with a median follow-up of 7.8 (4.1-12.1) years. The overall HR of UDCA was 0.46 (95% CI 0.40 to 0.52) and the 5-year LT-free survival without UDCA was 81% (95% CI 79 to 82). The NNT to prevent one LT or death within 5 years (NNT5y) was 11 (95% CI 9 to 13). Although the HR of UDCA was similar for patients with and without cirrhosis (0.33 vs 0.31), the NNT5y was 4 (95% CI 3 to 5) and 20 (95% CI 14 to 34), respectively. Among patients with low alkaline phosphatase (ALP) (≤2× the upper limit of normal (ULN)), intermediate ALP (2-4× ULN) and high ALP (>4× ULN), the NNT5y to prevent one LT or death was 26 (95% CI 15 to 70), 11 (95% CI 8 to 17) and 5 (95% CI 4 to 8), respectively. CONCLUSION: The absolute clinical efficacy of UDCA with respect to LT or death varied with baseline prognostic characteristics, but was high throughout. These findings strongly emphasise the incentive to promptly initiate UDCA treatment in all patients with PBC and may improve patient compliance.
引用
- Harms MH, de Veer RC, Lammers WJ, et al. Number needed to treat with ursodeoxycholic acid therapy to prevent liver transplantation or death in primary biliary cholangitis. Gut. 2019. PMID: 31843787. doi:10.1136/gutjnl-2019-319057
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。